| 1 |
35288835 | Pleiotropic effects of AT-1 receptor antagonists in hypoxia induced by cardiac ischaemia. | 2022 Mar 15 |
1 |
| 2 |
33599747 | Association of Cytochrome P450 2C9*3 and Angiotensin II Receptor 1 (1166A>C) Gene Polymorphisms With the Antihypertensive Effect of Irbesartan. | 2021 Feb 18 |
2 |
| 3 |
34174702 | Irbesartan suppresses lipopolysaccharide (LPS)-induced blood-brain barrier (BBB) dysfunction by inhibiting the activation of MLCK/MLC. | 2021 Sep |
1 |
| 4 |
34620946 | Irbesartan, an angiotensin II type 1 receptor blocker, inhibits colitis-associated tumourigenesis by blocking the MCP-1/CCR2 pathway. | 2021 Oct 7 |
1 |
| 5 |
32087363 | Systematic characterization of AT1 receptor antagonists with label-free dynamic mass redistribution assays. | 2020 Mar - Apr |
1 |
| 6 |
31511361 | AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis. | 2019 Nov |
1 |
| 7 |
29657902 | Inhibitory Effects of Angiotensin II Receptor Blockade on Human Tenon Fibroblast Migration and Reactive Oxygen Species Production in Cell Culture. | 2018 Apr |
1 |
| 8 |
28400916 | Angiotensin receptor blocker drugs and inhibition of adrenal beta-arrestin-1-dependent aldosterone production: Implications for heart failure therapy. | 2017 Mar 26 |
1 |
| 9 |
27403534 | Nanoparticle-Mediated Delivery of Irbesartan Induces Cardioprotection from Myocardial Ischemia-Reperfusion Injury by Antagonizing Monocyte-Mediated Inflammation. | 2016 Jul 11 |
1 |
| 10 |
25631300 | Suppression of adrenal βarrestin1-dependent aldosterone production by ARBs: head-to-head comparison. | 2015 Jan 29 |
1 |
| 11 |
23386284 | Irbesartan-mediated AT1 receptor blockade attenuates hyposmotic-induced enhancement of I Ks current and prevents shortening of action potential duration in atrial myocytes. | 2014 Dec |
2 |
| 12 |
23608606 | Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension. | 2013 Apr 22 |
1 |
| 13 |
24195292 | Pharmacokinetics and pharmacodynamics (PK/PD) of irbesartan in Beagle dogs after oral administration at two dose rates. | 2013 |
1 |
| 14 |
22426690 | Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling. | 2012 Jun |
3 |
| 15 |
22842919 | Inhibition of angiotensin II-induced contraction of human airway smooth muscle cells by angiotensin-(1-7) via downregulation of the RhoA/ROCK2 signaling pathway. | 2012 Oct |
1 |
| 16 |
23237398 | [Irbesartan in clinical practice]. | 2012 |
1 |
| 17 |
21346624 | Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartan. | 2011 May |
3 |
| 18 |
21703011 | Altered efficacy of AT1R-targeted treatment after spontaneous cancer cell-AT1R upregulation. | 2011 Jun 26 |
4 |
| 19 |
21949635 | Long-term use and tolerability of irbesartan for control of hypertension. | 2011 |
1 |
| 20 |
20649581 | Irbesartan treatment up-regulates hepatic expression of PPARalpha and its target genes in obese Koletsky (fa(k)/fa(k)) rats: a link to amelioration of hypertriglyceridaemia. | 2010 Aug |
1 |
| 21 |
20826135 | Irbesartan enhances GLUT4 translocation and glucose transport in skeletal muscle cells. | 2010 Dec 15 |
1 |
| 22 |
22993591 | Effects of irbesartan on 24-h blood pressure changes and urinary albumin levels in Japanese outpatients. | 2010 Jul |
1 |
| 23 |
18300863 | Effects of angiotensin II type 1-receptor blockade on retinal endothelial function. | 2008 Mar |
1 |
| 24 |
18464745 | The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial. | 2008 Jul |
8 |
| 25 |
18627212 | Irbesartan: a review of its use in hypertension and diabetic nephropathy. | 2008 |
2 |
| 26 |
17637792 | Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: results from the SILVHIA study. | 2007 Dec |
1 |
| 27 |
16109807 | Influences of AT1 receptor blockade on tissue metabolism in obese men. | 2006 Jan |
1 |
| 28 |
16298156 | Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. | 2006 |
2 |
| 29 |
16794485 | Carvedilol-induced antagonism of angiotensin II: a matter of alpha1-adrenoceptor blockade. | 2006 Jul |
1 |
| 30 |
15662225 | Enhanced angiotensin II-mediated effects in fibroblasts of patients with familial hypercholesterolemia. | 2005 Feb |
3 |
| 31 |
16261944 | [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ]. | 2005 Oct 6 |
1 |
| 32 |
14716224 | AT1 and AT2-receptor antagonists inhibit Ang II-mediated facilitation of noradrenaline release in human atria. | 2004 Feb |
1 |
| 33 |
15037537 | Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. | 2004 Mar 30 |
1 |
| 34 |
15154711 | Irbesartan has a masking effect on dipyridamole stress induced myocardial perfusion defects. | 2004 Feb |
2 |
| 35 |
16739358 | [Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice]. | 2004 Aug 5 |
1 |
| 36 |
12626661 | Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1. | 2003 Jun |
1 |
| 37 |
14605589 | The antihypertensive response to irbesartan treatment from a pharmacogenetic perspective. | 2003 Aug |
1 |
| 38 |
15030294 | AT1-receptor antagonism in hypertension: what has been learned with irbesartan? | 2003 May |
3 |
| 39 |
11791028 | Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. | 2002 Jan |
2 |
| 40 |
11904530 | Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans. | 2002 Apr |
1 |
| 41 |
11910301 | Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. | 2002 Apr |
1 |
| 42 |
11963637 | [Efficacy-safety relationship of AT1 angiotensin II receptor antagonists: current data]. | 2002 Jan-Feb |
1 |
| 43 |
11996640 | Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy. | 2002 May |
2 |
| 44 |
12035877 | Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartan. | 2002 |
1 |
| 45 |
12045789 | Vascular changes in hypertension in response to drug treatment: Effects of angiotensin receptor blockers. | 2002 May |
1 |
| 46 |
12134723 | [ACE inhibitor or AT1 antagonist. Is there a differential therapy?]. | 2002 Jun 13 |
1 |
| 47 |
12184030 | [Irbesartan--antihypertensive treatment in patients with heart failure and diabetes mellitus]. | 2002 |
6 |
| 48 |
11403367 | Regression of left ventricular hypertrophy in human hypertension with irbesartan. | 2001 Jun |
3 |
| 49 |
11683476 | Pharmacology of AT1-receptor blockers. | 2001 |
1 |
| 50 |
11206708 | Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors. | 2000 Nov-Dec |
2 |